VYNE Therapeutics Investor Presentation June 2022

VYNE Therapeutics is developing proprietary therapies for immuno-inflammatory conditions, including atopic dermatitis and rare skin diseases. The company's pipeline includes JAK/sphingosine-1 receptor modulator combinations and BET inhibitors through its novel InhiBET platform, with multiple near-term catalysts across clinical candidates VYN201 and VYN202.